Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Recent & Breaking News (NEO:CYBN)

Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders

Business Wire February 9, 2022

The StockTalk Cannabis Report: Feb 4, 2022

Dave Jackson February 4, 2022

Cybin Announces Additional Adelia Milestone Achievement

Business Wire January 27, 2022

Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022

Business Wire January 27, 2022

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Business Wire January 11, 2022

Cybin Announces Additional Adelia Milestone Achievement

Business Wire January 6, 2022

Cybin Provides 2021 Year End Summary

Business Wire December 22, 2021

Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference

Business Wire December 21, 2021

Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders

Business Wire December 15, 2021

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Business Wire December 8, 2021

The StockTalk Cannabis Report: Dec 3, 2021

Dave Jackson December 3, 2021

Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021

Business Wire December 1, 2021

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

Business Wire November 30, 2021

Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Business Wire November 29, 2021

Cybin announces additional Adelia Therapeutics milestone achievements

Stockhouse Editorial November 29, 2021

Cybin Announces Additional Adelia Milestone Achievements

Business Wire November 26, 2021

The StockTalk Cannabis Report: Nov 26, 2021

Dave Jackson November 26, 2021

Cybin awards grant for psychedelic treatment clinic

Stockhouse Editorial November 24, 2021

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Business Wire November 23, 2021

Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

Business Wire November 15, 2021